Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
The most effective method to Pick the Ideal Lab Precious stone Wedding band - 2Step by step instructions to Contrast Lab Jewels and Regular Ones
- 3Figure out how to Consolidate All encompassing Practices with a Degree in Brain research
- 4Hot Electric Vehicles for 2023
- 57 Strange Apparatuses to Make Your Party Stick Out!
- Accor signs agreement to transform El Gouna resort as Sofitel
- Top Smoothie Flavor: What's Your Mix?
- When fake data is a good thing – how synthetic data trains AI to solve real problems
- RFK Jr. wants to scrutinize the vaccine schedule – but its safety record is already decades long
- What’s your chronotype? Knowing whether you’re a night owl or an early bird could help you do better on tests and avoid scams
- UAE recalls some Nestle infant formula products, Qatar warns consumers
- Air India chief resigns 10 months after devastating Ahmedabad crash and amid mounting financial troubles
- IDF continues counterterrorism operations in Gaza Strip, including destroying terror tunnels
- Reclassifying Achievement: Individual Accounts of Seeking after Interests
